Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
Aged
Combined Modality Therapy
Female
Fluorodeoxyglucose F18
Follow-Up Studies
Humans
Lung Neoplasms
/ diagnostic imaging
Male
Mesothelioma
/ diagnostic imaging
Mesothelioma, Malignant
Middle Aged
Pleural Neoplasms
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Prognosis
ROC Curve
Radiopharmaceuticals
Retrospective Studies
Survival Rate
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
09
2019
accepted:
03
02
2020
entrez:
19
2
2020
pubmed:
19
2
2020
medline:
10
5
2020
Statut:
epublish
Résumé
The maximum standardized uptake value (SUVmax) in 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) may be of prognostic significance for patients with malignant pleural mesothelioma (MPM). This retrospective study aimed to investigate the prognostic value of the SUVmax in patients with MPM. Medical records were retrospectively reviewed for the patients who were diagnosed with histopathologically proven MPM between 2009 and 2018 at Samsung Medical Center. For each patient, SUVmax was calculated for the primary lesion on PET/CT. To determine optimal cutoff values for predicting mortality, receiver operating characteristic curves were used. Among the 54 study patients, 34 (63.0%) had epithelioid subtype, 13 (24.1%) had sarcomatoid or biphasic subtype, and 7 (13.0%) had mesothelioma, not otherwise specified (NOS). The median overall survival (OS) was 8.7 months, and the median SUVmax was 9.9. The median values of SUVmax were 5.5 in patients with epithelioid subtype, 11.7 in those with sarcomatoid/biphasic subtype, and 13.3 in those with NOS subtype (P = 0.003). The optimal cutoff values of SUVmax to predict mortality were 10.1 in all patients, and 8.5 in patients with epithelioid subtype. In multivariate analysis, SUVmax was significantly associated with overall survival in all patients (P = 0.003) and in patients with epithelioid subtype (P = 0.012), but not in those with non-epithelioid subtype. SUVmax in PET/CT is an independent prognostic factor in patients with MPM, especially those with epithelioid subtype. The histologic subtype of MPM should be considered when evaluating the prognostic significance of SUVmax.
Identifiants
pubmed: 32069313
doi: 10.1371/journal.pone.0229299
pii: PONE-D-19-27290
pmc: PMC7028266
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229299Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Radiol. 2019 Mar;74(3):207-215
pubmed: 30638733
Radiat Oncol. 2015 Dec 30;10:267
pubmed: 26715491
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):276-82
pubmed: 24057459
Lancet Oncol. 2017 May;18(5):623-630
pubmed: 28291584
Ann Oncol. 2013 Apr;24(4):1005-10
pubmed: 23136224
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Lancet Oncol. 2011 Aug;12(8):763-72
pubmed: 21723781
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
J Clin Oncol. 1998 Jan;16(1):145-52
pubmed: 9440736
J Thorac Cardiovasc Surg. 2006 Oct;132(4):763-8
pubmed: 17000285
J Thorac Oncol. 2016 Dec;11(12):2089-2099
pubmed: 27687963
Br J Cancer. 2014 Jul 15;111(2):220-6
pubmed: 24918816
J Clin Oncol. 2009 Jun 20;27(18):3007-13
pubmed: 19364962
Chest. 1998 Mar;113(3):723-31
pubmed: 9515850
J Thorac Oncol. 2007 Oct;2(10):957-65
pubmed: 17909360
Lancet Respir Med. 2019 Mar;7(3):260-270
pubmed: 30660511
Clin Lung Cancer. 2013 Jan;14(1):70-7
pubmed: 22658812
Eur J Cancer. 2012 May;48(8):1244-54
pubmed: 22330319
Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):667-75
pubmed: 25403555
J Clin Oncol. 2006 Oct 1;24(28):4587-93
pubmed: 17008700
Thorac Surg Clin. 2016 Aug;26(3):359-75
pubmed: 27427530
J Thorac Oncol. 2016 Feb;11(2):249-55
pubmed: 26845118
Mol Imaging Biol. 2009 Nov-Dec;11(6):473-9
pubmed: 19330385
J Thorac Oncol. 2012 Jul;7(7):1192-7
pubmed: 22617244